Case report: Ceftriaxone-linked renal toxicity in adult male

Case report: ceftriaxone-linked renal toxicity in adult male

(HealthDay)—A case of ceftriaxone-associated renal toxicity in an adult has been documented in a case report published online Feb. 23 in the Journal of Clinical Pharmacy and Therapeutics.

W. Shen-hua, M.D., from Zhejiang University in Hangzhou, China, and colleagues describe a case of ceftriaxone-associated urolithiasis and post-renal acute (PARF) in a 25-year-old male. The patient developed colicky abdominal pain, anuria, and bilateral renal colic during administration of intravenous ceftriaxone. Ceftriaxone administration was discontinued immediately.

The researchers identified elevated serum creatinine, and urinary tract ultrasound revealed bilateral mild hydronephrosis and proximal ureterectasia. Bilateral ureteropyelectasia and contrast medium failed to fill bilateral pelvises and ureters on abdominal enhanced computed tomography. The patient did not respond to pharmacotherapy. Following double J stent insertions by cystoscopy, the symptoms were resolved and was normalized.

"Overdose of ceftriaxone was related to urolithiasis and PARF in adults. Multidetector-row computed tomography and maximum intensity projections were efficient and effective in identifying ceftriaxone-associated urolithiasis," the authors write. "Treatment should be optimized, including prompt J stent insertions by cystoscopy."


Explore further

Non-HIV-related kaposi sarcoma in BRAFi-treated patient

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Case report: Ceftriaxone-linked renal toxicity in adult male (2016, March 21) retrieved 7 March 2021 from https://medicalxpress.com/news/2016-03-case-ceftriaxone-linked-renal-toxicity-adult.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments